share_log

明德生物(002932.SZ)：拟斥资1.75亿元-3.50亿元回购公司股份

Matilda Biotech (002932.SZ): Plans to spend 175 million yuan to 350 million yuan to buy back the company's shares

Gelonghui Finance ·  Mar 1 05:05

Gelonghui March 1 | Mingde Biotech (002932.SZ) announced that the company plans to buy back the company's shares through centralized bidding transactions, which are intended to be used for employee stock ownership plans or equity incentives, and to protect the company's value and shareholders' rights. The total repurchase capital shall not be less than RMB 17,500.00 (inclusive), and not more than RMB 350,000 (inclusive). Among them, the total amount of repurchase capital used for employee stock ownership plans or equity incentives is not less than RMB 7,500.00 (inclusive) and not more than RMB 15,000 (inclusive), and the total share repurchase capital used to protect the company's value and shareholders' rights is not less than RMB 10,000.00 (inclusive) and not more than RMB 20,000.00 (inclusive) 10,000 yuan (inclusive). The share repurchase price does not exceed RMB 23 per share. The implementation period for share repurchase for employee stock ownership plans or share incentives is within 12 months from the date the company's shareholders' meeting reviews and approves the share repurchase plan; the implementation period necessary to maintain the company's value and shareholders' rights is within 3 months from the date the company's shareholders' meeting reviews and approves the share repurchase plan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment